217 related articles for article (PubMed ID: 25010984)
1. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
[TBL] [Abstract][Full Text] [Related]
2. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
Saha MN; Jiang H; Mukai A; Chang H
Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
[TBL] [Abstract][Full Text] [Related]
3. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
[TBL] [Abstract][Full Text] [Related]
4. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
5. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
6. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
7. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
9. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
[TBL] [Abstract][Full Text] [Related]
10. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
[TBL] [Abstract][Full Text] [Related]
11. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
12. Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53.
Choe YJ; Lee SY; Ko KW; Shin SJ; Kim HS
Int J Oncol; 2014 Mar; 44(3):761-8. PubMed ID: 24366007
[TBL] [Abstract][Full Text] [Related]
13. Chk2 mediates RITA-induced apoptosis.
de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
[TBL] [Abstract][Full Text] [Related]
14. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
15. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
16. RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways.
Mobaraki RN; Karimi M; Alikarami F; Farhadi E; Amini A; Bashash D; Paridar M; Kokhaei P; Rezvani MR; Kazemi A; Safa M
Anticancer Drugs; 2018 Oct; 29(9):847-853. PubMed ID: 30157040
[TBL] [Abstract][Full Text] [Related]
17. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
[TBL] [Abstract][Full Text] [Related]
19. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
[TBL] [Abstract][Full Text] [Related]
20. RITA enhances irradiation-induced apoptosis in p53-defective cervical cancer cells via upregulation of IRE1α/XBP1 signaling.
Zhu H; Abulimiti M; Liu H; Su XJ; Liu CH; Pei HP
Oncol Rep; 2015 Sep; 34(3):1279-88. PubMed ID: 26134873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
